Popular Articles
Natural Remedies

Three New Studies Give Clear Guidance On How To Better Recruit Volunteers For Alzheimer's Clinical Studies
Partnering with local physicians, working with local clinics, conducting educational seminars and health fairs were found to be the most effective tools in recruiting people for clinical studies
generic viagra online
Hunger Hormone Fired Up By Fatty Foods, Not Empty Stomach
New research led by the University of Cincinnati (UC) suggests that the hunger hormone ghrelin is activated by fats from the foods we eat - not those made in the body - in order to optimize nutrient metabolism and promote the storage of body fat.
News of the day
Boston Globe Examines Hospital's Attempt To Reduce Emergency Department Visits, Hospital Stays Among Elderly
Efforts by Massachusetts General Hospital to reduce health spending could be indicative of the difficulty the health industry faces in trying to reduce spending growth, the Boston Globe reports. Industry groups last week pledged to seek a 1.5% overall reduction in health care spending over the next 10 years.Massachusetts General"s program, which began in 2006, aims to reduce hospitalizations among the elderly by 15% to 20%, as well as to improve the quality of care the elderly receive. A study looking at 35 efforts to improve elderly care found that only six, including Massachusetts General"s program, saved money or covered their costs, the Globe reports. Massachusetts General"s program relies on nurses in primary care practices to be in regular contact with patients and provide assistance with nonmedical services. The program also uses electronic health records to coordinate care. The hospital spent $8 million to $9 million over the first three years of the program to provide enhanced services to patients. Hospital readmissions fell by 19%, admissions decreased by 17% and ED visits dropped by 15% between 2007 and 2008, according to preliminary research. The program saved enough by reducing hospital admissions and emergency department visits to cover its costs and also to generate savings of $7 million to $10 million. The overall cost for the program was about 5% less than for a group of other patients treated in a more traditional way.According to Harvard University health care economist David Cutler, improving care and reducing costs among the elderly is a necessary component of health reform. He said, "If we can"t do this, it doesn"t bode well for health reform." Eric Weil, a primary care physician and medical director of the program at Massachusetts General, said, "Medicare is looking for any and every way to save money," adding, "This is a population of patients who are sick and will get sicker over time. Any opportunity to demonstrate savings in this group of patients is good, and 5% is very good" (Kowalczyk, Boston Globe, 5/17).
Public Health

SNM's Clinical Trials Network Gains Added Support From Industry Leader

The SNM Clinical Trials Network, an initiative designed to address the need for streamlined drug discovery through the integration of imaging biomarkers into multi-center clinical trials, recently added Genentech, Inc. as a supporter. SNM, the world"s largest medical and scientific society for molecular imaging professionals, inaugurated the Clinical Trials Network in late 2008 to facilitate more cost-effective drug development through the integration and standardization of imaging biomarkers into Phase 1, 2, 3 and 4 therapeutic clinical trials. As part of this initiative, the society continues to bring together pharmaceutical developers, the imaging community, biomarker manufacturers and regulatory agencies to address critical needs for incorporating imaging biomarkers into multi-center trials. A formal introduction to the Clinical Trials Network was provided at a two-day workshop in Clearwater Beach, Fla. in February 2009 and additional educational sessions about the network are planned for June during SNM"s 56th Annual Meeting in Toronto, Canada. "We are gratified to have Genentech - a pioneer in the field of developing targeted therapeutics - join us in this important endeavor, which we hope will broaden the scope and effectiveness of today"s medical practice and lead to improved patient care in the near future," said Peter S. Conti, M.D., Ph.D., co-chair of the SNM Clinical Trials Network and professor of radiology, pharmacy and biomedical engineering at the University of Southern California. "We are pleased that such an innovative corporate leader supports our mission of advancing molecular imaging and therapy." The use of imaging in clinical trials can help pharmaceutical developers determine earlier in the development process whether a new product is clinically promising by allowing physicians to see and assess whether it is working as intended for a patient, explained Dr. Conti. "Molecular imaging is an essential component of such studies since it accelerates the development of promising compounds and eliminates those without apparent patient benefit earlier in the development cycle," he added. "We hope that Genentech"s collaboration with SNM will help improve patient treatment worldwide." Amy Shaw Society of Nuclear Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):